Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06124846
Other study ID # PSYCH-2023-32396
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 1, 2024
Est. completion date April 15, 2028

Study information

Verified date April 2024
Source University of Minnesota
Contact Allison Corlett
Email corle050@umn.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to understand the changes in neural correlates of reward in adolescents with and without Cannabis Use Disorder (CUD). The study will collect functional magnetic resonance imaging (fMRI) data at 3 different timepoints with the primary goals of understanding striatal reward-based activation during a Monetary Incentive Delay Task and fronto-striatal fMRI resting-state functional connectivity. The study will also explore self-reported impulsivity. The long-term goal is to advance scientific understanding of neural changes associated with cannabis abstinence and inter-individual variability that cannot be otherwise measured in preexisting observational cohorts such as the Adolescent Brain Cognitive Development Study. This parallel intervention study will collect fMRI data in adolescents ages 15-18 years old with and without CUD at three different timepoints over the course of their intervention. Utilizing a validated paradigm, adolescents with CUD will be randomized to 6-weeks of either incentivized, biochemically verified abstinence via contingency management or monitoring with no required abstinence. Age- and sex-matched adolescents with no lifetime history of cannabis use will also complete the protocol. Participants will complete 8 study visits (3 with fMRI scans) involving urinalysis to confirm cannabis self-report and measures of impulsivity.


Recruitment information / eligibility

Status Recruiting
Enrollment 64
Est. completion date April 15, 2028
Est. primary completion date April 15, 2028
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 15 Years to 18 Years
Eligibility Inclusion Criteria: - Male and female adolescents between the ages of 15 and 18 (inclusive). - Have a parent or legal guardian who is able and willing to provide written informed consent. - Competent and willing to provide written informed assent (participants <18) or consent (participants=18). - Native English speaker. - Have a parent or legal guardian who is fluent in English. - Able to commit to 8 study visits in approximately 60 days (6 weeks). - Able to safely participate in the protocol and appropriate for outpatient level of care, in the opinion of the PI. - No active psychosis or current use of antipsychotic medications. - Participants taking psychotropic medications will be included if the medications have been stable for 6 weeks and are expected to remain stable for the duration of their study participation (i.e., through the third MRI). - For CB-Abst (n=24) and CB-Mon (n=20) groups: at least 5 days of use per week on average in the past two months and meet DSM-V cannabis use disorder (CUD; at least Mild) criteria. Cannabis use reported within seven days of baseline visit. Positive qualitative urine toxicology test at baseline for THC. No immediate plan to discontinue cannabis use. - For Con (n=20): no lifetime history of cannabis use. Negative qualitative urine toxicology test at baseline for THC. No immediate plans to begin cannabis use. Exclusion Criteria: - Past twelve-month history of substance use disorders (except for Cannabis Use Disorder in CB-Abst and CB-Mon), assessed via semi-structured psychodiagnostics interview at baseline. - Current daily nicotine use (e.g., via electronic and/or combustible cigarettes). - Contraindications for MRI (ascertained via participant and parent report), including but not limited to: 1. Metal implants such as surgical clips or pacemakers, or history of working with metal, unless the possibility of a metal fragment can be ruled out by recent orbital scans. 2. Prior head trauma with neurological sequelae. 3. Claustrophobia. 4. Weight incompatible with MRI safety. 5. Pregnancy. - Previous or current diagnosis of psychosis, cognitive disability, or bipolar disorder. - Active suicidality. - Taking a psychotropic medication that has not reached stability criterion (same medication type and dose for 6 weeks with no planned changes over the study period). - Any other medical or psychiatric condition deemed serious or contraindicated for any study procedures by Dr. Tervo-Clemmens.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
CB-Abst
incentivized, biochemically verified abstinence via contingency management
CB-Mon
monitoring with no required abstinence

Locations

Country Name City State
United States University of Minnesota Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Brain activation during Monetary Incentive Delay Task (reward processing) A neural measure of reward activation will be defined as the difference between reward positive vs negative feedback in the standardized Harvard Oxford Striatal atlas during the MID Task. baseline, week3, week 6
Primary Brain connectivity during resting-state functional neuroimaging protocol A neural measure of reward-circuitry connectivity will be defined as the correlation values between standardized striatal and salience and orbitofrontal and salience cortical networks baseline, week 3, week 6
Secondary Self-reported Impulsivity via UPPS-P scale Self-reported impulsivity will be defined by Total and Premeditation (lack of), Urgency, Sensation Seeking, Perseverance (lack of) scores baseline, weeks 1,2,3,4,5 and 6
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05726617 - Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders N/A
Not yet recruiting NCT04139668 - Vivitrol Treatment for Cannabis Use Disorder Phase 2
Completed NCT01656707 - Adaptive Treatment for Adolescent Cannabis Use Disorders N/A
Completed NCT03204305 - Brain Imaging of Cannabinoid Receptors Early Phase 1
Completed NCT05005013 - A Teleheath tDCS Approach to Decrease Cannabis Use N/A
Recruiting NCT05292547 - Repetitive Transcranial Magnetic Stimulation to People With Cannabis Use Disorder (SToP-C-rTMS x CUD) N/A
Completed NCT02932215 - Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder Phase 1
Completed NCT03430050 - Progesterone for Cannabis Withdrawal Early Phase 1
Withdrawn NCT03629106 - Effects of Cannabis Abstinence on Symptomology and Cognition in Bipolar Disorder N/A
Completed NCT03334721 - Gabapentin for Bipolar & Cannabis Use Disorders Phase 2
Recruiting NCT04721353 - Reducing Cannabis Overuse With Prazosin Phase 4
Completed NCT03718520 - The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity
Completed NCT03624933 - Effects of Cannabis Abstinence on Symptoms and Cognition in Depression N/A
Recruiting NCT05836207 - Rewards for Cannabis Abstinence-study N/A
Not yet recruiting NCT06114212 - Deep Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder N/A
Recruiting NCT05855668 - Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment N/A
Recruiting NCT04517474 - Comparing the Spanish Version of CANreduce With or Without Psychological Support and Treatment as Usual, Reducing Cannabis Use. N/A
Recruiting NCT05885542 - SCORE Emerging Adult Cannabis Use & Stress Phase 1/Phase 2
Not yet recruiting NCT06085222 - Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users Phase 1
Completed NCT03056482 - Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC) Phase 4